Evidence map›Paper›PMID 35940869›Full record

SynthesisJournal of medical virology2022

Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.

Raaka Kumbhakar, Moni Neradilek, Ruanne V Barnabas, Jenell Stewart, Helen C Stankiewicz Karita, Raphael J Landovitz, Patricia J Kissinger, Keith R Jerome, Michael K Paasche-Orlow, Anna Bershteyn and 7 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Raaka KumbhakarDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-6707-2397
Moni NeradilekVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Ruanne V BarnabasDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Jenell StewartDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Helen C Stankiewicz KaritaDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Raphael J LandovitzDepartment of Medicine, Division of Infectious Diseases, UCLA Center for Clinical AIDS Research & Education (CARE), University of California, Los Angeles, California, USA.
Patricia J KissingerSchool of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
Keith R JeromeVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Michael K Paasche-OrlowGeneral Internal Medicine, Boston University School of Medicine, Boston, Massachusettes, USA.
Anna BershteynDepartment of Population Health, New York University Grossman School of Medicine, New York, New York, USA.
Helen Y ChuDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Kathleen M NeuzilDepartments of Medicine and Pediatrics, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
Alexander L GreningerVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Alfred LukDepartment of Medicine, School of Medicine, Tulane University, New Orleans, Louisiana, USA.
Anna WaldDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Elizabeth R BrownVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Christine JohnstonDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-3073-0843

Funding

VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA TrialR01CA213130 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MADELEINE, MARGARET M, WALD, ANNA · 2017 to 2022
$4.6M
NCI NIH HHS R01 CA213130NIAID NIH HHS T32 AI007140NIH HHS
6 · The paper itself

Abstract

Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either postexposure prophylaxis or early treatment of SARS-CoV-2 infection. Using data from these studies, we calculated the time-weighted average change from baseline SARS-CoV-2 viral load and demonstrated that HCQ did not affect viral clearance.

Indexed as

COVID-19COVID-19 Drug TreatmentSARS-CoV-2HumansHydroxychloroquineViral LoadHydroxychloroquineCOVID-19early treatmenthydroxychloroquinePEPSARS-CoV-2

Identifiers

PMID35940869
PMCPMC9538473

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.